Cochlear Targets Adult-Care Growth After Challenging Year
Closing price · 2026-10-26: $141.82 · -3.40%
Cochlear’s chair said FY26 performance fell below expectations, citing healthcare capacity constraints, insurance delays, reimbursement changes and other operating pressures. The company is accelerating cost reductions and a more scalable operating model while expanding clinician-led referral pathways to reach more adults with severe hearing loss; its guidelines are being implemented across 25 countries. The excerpt also says Professor Ian Meredith will join the board as an independent non-executive director in December.